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Background: Although a great deal of research has focused
on patient quality of life (QOL) after hematopoietic cell
transplant (HCT), studies of caregivers are relatively scarce.
The goal of the current study was to conduct a qualitative
analysis of caregiver QOL after HCT.
Methods: As part of a larger qualitative study examining
patient education regarding post-transplant QOL, caregivers
of patients who had received HCT one to four years previ-
ously were recruited. Participants attended one of four
caregiver-only focus groups. Caregivers were asked to
describe their own QOL after the transplant, how their QOL
differed from what they expected before the transplant, the
most important things they did to improve their QOL, and
how to best educate future HCT caregivers. Verbatim tran-
scripts were coded for a priori and emergent themes using
content analysis.
Results: A total of 15 caregivers participated (67% female,
mean age 57, range 25-65). A major theme was caregivers’
feelings of helplessness and guilt about their inability to ease
patients’ physical and emotional suffering. Caregivers also
emphasized the challenges of caring for the patient while
taking on many of the patient’s previous responsibilities at
home. Many caregivers also struggled with the demands of
raising children and working while caregiving. Another
major theme was ambivalence about leaving the house;
caregivers reported feelings of liberation but also guilt and
worry about leaving the patient at home. Regarding coping,
caregivers reported deriving beneﬁt from religion and spir-
ituality, social support, and activities that helped them
maintain their own sense of identity. Participants described a
desire for more caregiver support programs at the transplant
center as well as informal networks of other HCT caregivers
in their community.
Conclusions: Findings underscore the emotional and phys-
ical challenges of caring for a HCT recipient. Additional ef-
forts are needed to facilitate psychosocial support addressing
caregivers’ unique concerns.
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Background: Hematopoietic stem cell transplantation
(HSCT) has become a standard component of therapy for
several pediatric malignancies. As HSCT improves survival
among those afﬂicted with these malignancies, and sup-
portive care advances diminish the acute toxicities of HSCT,
the risk for late complications in survivors is of increasing
concern. We have recently shown that nearly 80% ofpatients survive beyond 2-years after HSCT. However,
knowledge regarding the burden of morbidity after HSCT
once survivors reach adulthood is sparse. Frequency of
hospitalizations can serve as a proxy measure of morbidity
in this population.
Objectives: To assess the number of hospitalization episodes
in long-term adult survivors of childhood malignancies
treated with HSCT in a tertiary center.
Methods: We used record linkage between the SickKids’
clinical transplant database, the Canadian Province of
Ontario’s pediatric cancer registry (POGONIS) and health
care utilization data housed at the Institute for Clinical
Evaluative Sciences (ICES). The study population included all
adult survivors (age  18 years) of childhood cancer diag-
nosed prior to age 18 years between 1986 and 2005, who had
received cancer therapy that included an allogeneic or
autologous HSCT at SickKids, and who had survived more
than 5 years from transplant. Hospitalizations were captured
from the later of each survivor’s 18th birthday or 5 years after
HSCT until the end of the follow-up period (Dec 2011) or
death.
Results: The cohort consisted of 242 long-term adult survi-
vors who were followed for a mean of 12.3 years. Of these,
148 underwent allogeneic and 86 autologous HSCT. Mean
age at HSCT for the allogeneic group was 11.5 y (SD: 4.7) and
11.0 y (SD: 5.3) for the autologous group. A total of 262
hospitalizations were documented in adults post allogeneic
HSCT, representing a rate of 0.15 hospitalizations per follow-
up year. Univariate analysis revealed that age >10 years at
cancer diagnosis (RR¼3.53, 95% CI: 2.34-5.33), age >10 years
at HSCT (RR¼5.88, 95% CI: 2.89-11.85), and female gender
(RR¼1.70, 95% CI: 1.33-2.18) were associated with an
increased rate of hospitalization. The underlying diagnosis,
ALL vs. AML was not associated with increased rate of hos-
pitalization despite the use of total body irradiation among
ALL patients. A total of 106 hospitalizations were docu-
mented in adults post autologous HSCT, representing a rate
of 0.09 hospitalizations per follow-up year. Age >10 y-o at
time of HSCT (RR¼2.29, 95% CI: 1.29-4.04) and female gender
(RR¼1.70, 95% CI: 1.15-2.52) were associated with increased
rate of hospitalization.
Conclusions: We have identiﬁed risk factors for hospitali-
zation in adults who underwent HSCT during childhood. Age
> 10 years at time of HSCT and female gender were associ-
ated with increased risk for hospitalization. Our future
studies focus on length of stay and the indications for these
hospitalizations.209
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Allogeneic stem cell transplantation (SCT) with both mye-
loablative (MAC) and reduced intensity conditioning (RIC) is
effective therapy in AML andMDS. There is paucity of data on
the long term outcome (beyond 10 years) following RIC due
Figure 1
Results of Serum Speciﬁc IgE (Immunocap) testing of tree nuts.
Component Reference Range
Almond IgE <0.35 KU/L 3.55 (H)
Almond Class 0 3 (H)
Brazil Nut IgE <0.35 KU/L 1.28 (H)
Brazil Nut Class 0 2 (H)
Cashew Nut IgE <0.35 KU/L 3.86 (H)
Cashew Nut Class 0 3 (H)
Hazel Nut IgE <0.35 KU/L 13.5 (H)
Hazel Nut Class 0 3 (H)
Macadamia Nut IgE <0.35 KU/L 0.74 (H)
Macadamia Nut Class 0 2 (H)
Peanut IgE <0.35 KU/L 1.56 (H)
Peanut Class 0 2 (H)
Pecan Nut IgE <0.35 KU/L 4.68 (H)
Pecan Nut Class 0 3 (H)
Pistachio IgE <0.35 KU/L 4.16 (H)
Pistachio Class 0 3 (H)
Walnut IgE <0.35 KU/L 35.60 (H)
Walnut Class 0 4 (H)
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previously reported on the role of dose intensity in a group of
112 patients (pts) with AML (n¼95) and MDS (n¼17) given
SCT with different regimens between 1999 and 2004 (Leu-
kemia 2006). Overall survival (OS) was similar with MAC and
RIC in pts given SCT in remission, but was inferior in pts given
RIC in active disease due to high relapse rates. We have now
updated SCT outcomes in the same cohort with a median
follow up of 10 years (8.5-12.5) in order to verify the original
ﬁndings with long follow up. The median age was 50 years
(18e70). 58 pts had active disease at SCT. The donor was
HLA-matched sibling (n¼58), or matched-unrelated (n¼54).
45 pts met eligibility criteria for standard MAC and were
given intravenous busulfan (ivBu, 12.8 mg/kg) and cyclo-
phosphamide (BuCy). 67 pts were considered non-eligible
for standard MAC and were given RIC with ﬂudarabine and
ivBu (6.4 mg/kg, FB2, n¼41) or reduced toxicity conditioning
(RTC) with ﬂudarabine and myeloablative doses of ivBu (12.8
mg/kg, FB4, n¼26). In all, 38 pts are alive and 74 have died, 48
relapse, 26 non-relapse mortality (NRM). MAC and RIC/RTC
had similar outcomes when leukemia was in remission at
SCT; 10-year OS been 47%, 50% and 47% after BuCy, FB4, and
FB2, respectively (p¼0.97). OS rates of pts with active disease
at SCT was 43%, 19% and 0%, respectively (p¼0.01) suggesting
an advantage for more intense regimens in this setting.
Relapse rates were higher after RIC/RTC than MAC
throughout the follow-up period. The rate was 30% and 18%,
1 year after SCT (p¼0.03), 37% and 20% after 2 years (p¼0.08),
49% and 27% after 5 years (p¼0.02) and 51% and 29% after 10
years (p¼0.02), respectively. NRM rates were higher after
MAC than RIC/RTC in the initial 2 years after SCT but
approached each other in the late post SCT course. NRM rate
was 22% and 9%, 1 year after SCT (p¼0.05), 22 and 10% after 2
years (p¼0.08), 22% and 15% after 5 years (p¼0.27), and 27%
and 19% after 10 years (p¼0.35), respectively. Thus, OS was
similar within the ﬁrst 2 years after SCT, 56% and 52% after
MAC and RIC/RTC, respectively (p¼0.86), but there was a
trend for better OS after MAC later on, 51% and 36%, 5 years
after SCT (p¼0.26) and 44% and 31%, 10 years after SCT
(p¼0.22), respectively. In conclusion, with long-term follow-
up ofmore than 10 years, RIC/RTC is an acceptable alternative
to MAC in ineligible pts. NRM is lower after RIC/RTC in the
early post SCT period, but late NRM negates this early
advantage. Relapse rates are higher after RIC/RTC throughout
the course. Due to these observations it seems an advantage
of MAC may become apparent 5-10 years after SCT. RIC/RTC
studies may need to be revisited with long (> 10 years)
follow up.210
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Background: Food allergy in children in the United States is
estimated to be approximately 8% and increasing yearly with
approximately 40% causing severe reactions requiring med-
ical intervention and possibly death. BMT donors are
screened for drug and food allergy because concern of po-
tential passive transfer of allergy with hematopoietic stem
cell transplantation.
Case report: We report a case of a 15 year old boy with
relapsed AML who underwent matched-related bone
marrow transplant from his non-identical twin brother
after myeloablative conditioning therapy with Busulfan-
Cyclophosphamide. His brother has a history of anaphy-
laxis to walnuts and pecans with conﬁrmatory skin testing
being positive for cashews, ﬁlbert nuts, pecans, and wal-
nuts prior to bone marrow transplant. Before trans-
plantation, our patient said he was able to eat tree nuts
including walnuts without difﬁculty. After the transplant
the patient avoided tree nuts and had skin prick testing
which showed large positives to tree nuts. Serum speciﬁc
IgE (sIgE) by Immunocap to tree nuts and peanut at his
one year post transplant evaluation showed (Figure 1) he
had a > 95% risk for anaphylaxis to walnuts with sIgE
positive to all other tested tree nuts and peanut. A diag-
nostic food challenge was not performed because of this
risk.
Conclusion: Bone marrow transplant physicians should be
more mindful of donor reported food allergies and
consider referral to an allergist for testing after trans-
plantation as passive transfer of IgE mediated food allergies
can occur.
